Pfizer Neurontin Patent Prompts Amendments To Three Of Nine ANDAs
Executive Summary
Pfizer has received updated Neurontin patent certifications from only three of the nine pending ANDA applicants seeking to market a generic version of the anti-epileptic gabapentin, the company told FDA in an Aug. 18 citizen's petition.